A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

Not yet recruiting

• Conditions: Heart Failure With Preserved Ejection Fraction; Coronary Microvascular Dysfunction

• Registration Number: NCT07093528
• Lead Sponsor: Mayo Clinic

Brief Summary

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-23
• Study First Submitted QC: 2025-07-23
• Last Update Submitted: 2025-07-23
• Study First Posted: 2025-07-30
• Last Update Posted: 2025-07-30
• Study Start: 2025-08-01
• Primary Completion: 2027-08
• Study Completion: 2027-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Age ≥18
• Enrollment in main CS-reducer HFPEF study IRB# 25-002292

Exclusion Criteria

• Metal implants that are not suitable for MRI
• Inability or unwillingness of individual to give written informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in endocardial:epicardial perfusion ratio	Baseline, 6 Months	Endocardial:Epicardial Perfusion Ratio is a measure of myocardial blood flow and will be determined by Cardiovascular magnetic resonance (CMR)

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States